Vidac Pharma

Skin Cancer Treatment

Health Tech & Life Sciences
Public on Hamburg Stock Exchange on Mar, 2023<br>

Company Overview

Snapshot

Founded in January 2012 by Professor Max Herzberg, Vidac Pharma operates with 1–10 employees. The company has raised $9 million across two funding rounds from four investors. Vidac Pharma went public on the Hamburg Stock Exchange in March 2023.

Business overview

Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for oncologic and dermatologic diseases. The company's technology targets the VDAC/HK2 system, which is unique to malignant cells, to induce selective apoptosis of cancer cells while sparing healthy tissue. Vidac Pharma's lead drug, VDA-1102, has completed a Phase 2b clinical trial for actinic keratosis and is in a Phase 2a clinical trial for Cutaneous T-Cell Lymphoma (CTCL). The company is also developing VDA-1275, a small-molecule new chemical entity for systemic treatment of solid tumors. Vidac Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical market.

Strategic signal

In September 2024, Vidac Pharma was granted a U.S. patent offering broad protection for the mode of action underlying its oncology drug candidates. This patent strengthens the company's intellectual property portfolio and validates its innovative approach to cancer treatment, signaling a robust foundation for future drug development and commercialization to investors.

Company Intelligence Q&A

When did Vidac Pharma go public?
Vidac Pharma went public on the Hamburg Stock Exchange in March 2023.
What was a key development for Vidac Pharma in September 2024?
In September 2024, Vidac Pharma was granted a U.S. patent providing broad protection for the mode of action of its oncology drug candidates.
What was a significant regulatory approval for Vidac Pharma in March 2024?
In March 2024, Vidac Pharma secured approval for the next phase of a clinical study for its lead asset in.
What patent development did Vidac Pharma announce in June 2024?
In June 2024, Vidac Pharma received a U.S. patent office Notice of Allowance for crucial compounds in its cancer drug candidates.
What clinical trial results did Vidac Pharma publish in July 2024?
In July 2024, Vidac Pharma published results from tests of its next-generation drug candidate in human and murine tumor models.

External links